SCHEMBL3607585

SCHEMBL3607585

CC(C)(C)c1ccc(S(=O)(=O)N2CCCN(c3ccccc3C(F)(F)F)CC2)cc1

nearest known ligand 0.91

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 15/20 0.91
LMNA P02545 1/20 0.56
GAA P10253 1/20 0.56
F13A1 P00488 1/20 0.56
TGM2 P21980 1/20 0.56
TGM1 P22735 1/20 0.56
ALDH1A1 P00352 1/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
KDM4E B2RXH2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3608843 0.85 HSD11B1 (1.00) HSD11B1
SCHEMBL3609740 0.82 HSD11B1 (0.62) HSD11B1LMNAGAAALDH1A1MEN1
SCHEMBL3226058 0.81 HSD11B1 (0.77) HSD11B1LMNAF13A1TGM2TGM1
SCHEMBL5360560 0.80 HSD11B1 (0.62) HSD11B1F13A1TGM2TGM1ALDH1A1
SCHEMBL3604873 0.80 HSD11B1 (1.00) HSD11B1
SCHEMBL4402433 0.78 LMNA (0.90) HSD11B1LMNAGAAALDH1A1MEN1
SCHEMBL3205817 0.78 HSD11B1 (0.76) HSD11B1LMNAGAAALDH1A1MEN1
SCHEMBL3198929 0.77 HSD11B1 (0.67) HSD11B1
SCHEMBL3214231 0.76 HSD11B1 (1.00) HSD11B1LMNAF13A1TGM2TGM1
SCHEMBL3222852 0.76 HSD11B1 (0.74) HSD11B1LMNAF13A1TGM2TGM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070173494-A1 Diaza heterocyclic sulfonamide derivatives and their uses AMGEN INC. 2007-07-26 US claimed
US-7825122-B2 Diaza heterocyclic sulfonamide derivatives and their uses AMGEN INC. (US) 2010-11-02 US disclosed
US-7825122-B2 Diaza heterocyclic sulfonamide derivatives and their uses AMGEN INC. (US) 2010-11-02 US disclosed
US-7825122-B2 Diaza heterocyclic sulfonamide derivatives and their uses AMGEN INC. (US) 2010-11-02 US disclosed
US-20100069380-A1 HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF PTC THERAPEUTICS, INC. 2010-03-18 US disclosed
WO-2008127274-A2 HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF PTC THERAPEUTICS, INC. (US) 2008-10-23 WO disclosed
US-20070173494-A1 Diaza heterocyclic sulfonamide derivatives and their uses AMGEN INC. 2007-07-26 US disclosed
US-20070173494-A1 Diaza heterocyclic sulfonamide derivatives and their uses AMGEN INC. 2007-07-26 US disclosed
US-20070173494-A1 Diaza heterocyclic sulfonamide derivatives and their uses AMGEN INC. 2007-07-26 US disclosed
WO-2007070506-A2 DIAZA HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USES AMGEN INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173494-A1 Diaza heterocyclic sulfonamide derivatives and their uses GLP1R, GPR119, INSR HSD11B1 685/4885LMNA 2635/4885GAA 963/4885
US-20100069380-A1 HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF NSUN3, TARBP1, TRMT1 HSD11B1 2674/4885LMNA 2706/4885GAA 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.